Arch Therapeutics, Inc. (ARTHQ)

Arch Therapeutics Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Revenue	0.15	0.08	0.02	0.01	-	-
Revenue Growth (YoY)	292.25%	383.80%	35.34%	-	-	-
Cost of Revenue	0.09	0.08	0.05	0.03	-	-
Gross Profit	0.06	-0	-0.04	-0.01	-	-
Selling, General & Admin	4.02	4.37	4.52	5.01	3.74	3.97
Research & Development	0.76	0.67	1.15	1.35	1.61	2.4
Operating Expenses	4.78	5.04	5.67	6.36	5.35	6.37
Operating Income	-4.72	-5.04	-5.71	-6.38	-5.35	-6.37
Interest Expense	-7.54	-3.1	-0.57	-0.15	-0.02	-
Other Non Operating Income (Expenses)	-	1.16	1	0.11	0.68	1.82
EBT Excluding Unusual Items	-12.26	-6.98	-5.28	-6.42	-4.69	-4.55
Other Unusual Items	-	-	-	0.18	-	-
Pretax Income	-12.26	-6.98	-5.28	-6.24	-4.69	-4.55
Net Income	-12.26	-6.98	-5.28	-6.24	-4.69	-4.55
Net Income to Common	-12.99	-6.98	-5.28	-6.24	-4.69	-4.55
Shares Outstanding (Basic)	6	3	1	1	1	1
Shares Outstanding (Diluted)	6	3	1	1	1	1
Shares Change (YoY)	339.38%	156.27%	9.05%	16.99%	13.05%	8.92%
EPS (Basic)	-2.35	-2.27	-4.40	-5.67	-4.99	-5.47
EPS (Diluted)	-2.35	-2.27	-4.40	-5.67	-4.99	-5.47
Free Cash Flow	-3.71	-3.38	-4.46	-5.96	-5.05	-5.27
Free Cash Flow Per Share	-0.67	-1.10	-3.71	-5.42	-5.37	-6.33
Gross Margin	39.58%	-3.22%	-228.96%	-127.26%	-	-
Operating Margin	-3186.90%	-6661.67%	-36473.33%	-55141.58%	-	-
Profit Margin	-8769.17%	-9221.43%	-33707.22%	-53960.07%	-	-
Free Cash Flow Margin	-2501.07%	-4461.91%	-28469.68%	-51551.26%	-	-
EBITDA	-4.72	-5.04	-5.71	-6.37	-5.35	-6.36
D&A For EBITDA	0	0	0	0	0.01	0.01
EBIT	-4.72	-5.04	-5.71	-6.38	-5.35	-6.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.